213 related articles for article (PubMed ID: 16311843)
1. Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.
Pinel S; Chastagner P; Merlin JL; Marchal C; Taghian A; Barberi-Heyob M
J Neurooncol; 2006 Jan; 76(1):31-8. PubMed ID: 16311843
[TBL] [Abstract][Full Text] [Related]
2. Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice.
Chastagner P; Kozin SV; Taghian A
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):777-82. PubMed ID: 11395247
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts.
Pinel S; Barberi-Heyob M; Cohen-Jonathan E; Merlin JL; Delmas C; Plenat F; Chastagner P
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):250-9. PubMed ID: 15093922
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma.
Zhang Y; Chen X; Ren P; Su Z; Cao H; Zhou J; Zou X; Fu S; Lin S; Fan J; Yang B; Sun X; Zhou Y; Chen Y; Yang L; Wu J
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):356-62. PubMed ID: 23906928
[TBL] [Abstract][Full Text] [Related]
5. In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice.
Chastagner P; Merlin JL; Marchal C; Hoffstetter S; Barberi-Heyob M; Vassal G; Duprez A
Clin Cancer Res; 2000 Aug; 6(8):3327-33. PubMed ID: 10955820
[TBL] [Abstract][Full Text] [Related]
6. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
Saito R; Krauze MT; Noble CO; Drummond DC; Kirpotin DB; Berger MS; Park JW; Bankiewicz KS
Neuro Oncol; 2006 Jul; 8(3):205-14. PubMed ID: 16723630
[TBL] [Abstract][Full Text] [Related]
7. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
8. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
9. Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):493-8. PubMed ID: 16563655
[TBL] [Abstract][Full Text] [Related]
10. Chronomodulation of topotecan or X-radiation treatment increases treatment efficacy without enhancing acute toxicity.
Mullins D; Proulx D; Saoudi A; Ng CE
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):230-7. PubMed ID: 15850926
[TBL] [Abstract][Full Text] [Related]
11. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
12. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
Papadopoulou MV; Bloomer WD; Hollingshead MG
Anticancer Res; 2005; 25(3B):1865-9. PubMed ID: 16158918
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of topotecan for pediatric central nervous system tumors.
Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases.
Kocher M; Eich HT; Semrau R; Güner SA; Müller RP
Strahlenther Onkol; 2005 Jan; 181(1):20-5. PubMed ID: 15660189
[TBL] [Abstract][Full Text] [Related]
16. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
17. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.
Friedman HS; Kerby T; Fields S; Zilisch JE; Graden D; McLendon RE; Houghton PJ; Arbuck S; Cokgor I; Friedman AH
Cancer; 1999 Mar; 85(5):1160-5. PubMed ID: 10091802
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model.
Dickson PV; Hagedorn NL; Hamner JB; Fraga CH; Ng CY; Stewart CF; Davidoff AM
J Pediatr Surg; 2007 Jan; 42(1):160-5; discussion 165. PubMed ID: 17208558
[TBL] [Abstract][Full Text] [Related]
19. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts.
Gridley DS; Archambeau JO; Andres MA; Mao XW; Wright K; Slater JM
Oncol Res; 1997; 9(5):217-27. PubMed ID: 9306429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]